Workflow
基因检测服务集采
icon
Search documents
江苏医保局率先向肿瘤基因检测回扣“开刀”
Jing Ji Guan Cha Wang· 2025-08-21 11:21
Core Viewpoint - Jiangsu Province is initiating a centralized procurement process for tumor gene testing services to reduce costs and regulate the industry, following a successful model for non-invasive prenatal genetic testing [1][2]. Group 1: Centralized Procurement Details - The procurement period is set for two years, focusing on various clinical samples using fluorescence quantitative PCR and high-throughput sequencing methods for tumor gene testing [2]. - The maximum effective bid for fluorescence quantitative analysis is set at 280 yuan per single site, while for high-throughput sequencing, it is 800 yuan per gene [2][3]. - The pricing structure aims to ensure that companies can still cover costs, although concerns exist regarding the potential impact on testing quality due to lower prices [3][5]. Group 2: Industry Impact and Adjustments - The centralized procurement is expected to disrupt the previous high-price model, allowing larger companies to negotiate better with hospitals, while smaller firms may struggle to compete [4][8]. - There is a possibility that companies might bid below cost to win contracts, which could negatively affect the quality of testing services [5][6]. - The procurement process is anticipated to reduce gray areas in the industry, as it eliminates the need for high commissions to doctors, thereby increasing price transparency [7][8]. Group 3: Financial Implications for Stakeholders - Sales personnel's income is likely to decrease significantly due to the reduced commission structure following centralized procurement, impacting their overall earnings [8]. - The previous practice of providing substantial kickbacks to doctors has diminished, with current rates dropping to around 20% for retail and below 15% for inpatient sales [6][8].